It's depressing to see an article like this six years after Reduce-It came out. No mention of reducing the chance of heart attacks or strokes by over 25 percent. The medical establishment six years after Reduce It still seems to think of Vascepa as a second thought to the beloved Lovaza, or, for many doctors, fish oil supplements. This article's description actually makes Lovaza sound preferable to Vascepa since it can treat anyone with "elevated triglyceride levels" whereas Vascepa is described as more of a niche medication only useful to those with "severe hypertriglyceridaemia," a much smaller patient population.
As the article put it:
"Lovaza/Omacor (omega-3 acid ethyl esters—semi-synthetic derivative of both EPA and DHA) is aimed at reducing elevated triglyceride levels. Vascepa (icosapent ethyl—synthetic derivative of EPA that has been purified to provide concentrated doses of EPA without including DHA) is primarily indicated for severe hypertriglyceridaemia."
Market Data 
Markets 
AI
